Acute Myeloid Leukemia (AML) is a malignant disease that occurs inside the bone marrow and rapidly spreads into the blood, mostly WBCs (White Blood Cells). It can affect different body parts like the liver, central nervous system, lymph nodes, spleen, and testicles. AML, among all forms of leukemia, has the lowest OS (overall survival) rate, i.e., five years, and can be fatal if left untreated. Some common symptoms of AML include breathlessness, skin discoloration, fatigue, weight loss, high body temperatures, & nosebleeds.
Chemotherapy, immunotherapy, targeted therapy, & hormonal therapies, and surgeries, are the most common AML treatments available globally, which are usually combined with stem cell transplants to reduce complications, enhance efficacy, and boost the immune system.
The Global Acute Myeloid Leukemia (AML) Market is projected to grow at a CAGR of around 13% during the forecast period, i.e., 2022-27. The market growth is fueled mainly by surging instances of genetic mutations, the growing geriatric population, & sedentary lifestyles that have resulted in the rapid rise in AML patients worldwide. As a result, governments and pharmaceutical companies of different countries worldwide are actively participating & massively investing in developing new drugs for its treatment.
|Study Period||Historical Data: 2017-20|
|Base Year: 2021|
|Forecast Period: 2022-27|
|Regions Covered||North America: The US, Canada, Mexico|
|South America: Brazil, Rest of South America|
|Europe: Germany, The UK, Germany France, Italy, Spain, Rest of Europe|
|Asia-Pacific: China, Japan, India, South Korea, Rest of Asia Pacific|
|Middle East & Africa: GCC, South Africa, Rest of Middle East and Africa|
|Key Companies Profiled||AstraZeneca PLC, AbbVie Inc., Baxter International Inc., Bayer AG, Bristol Myers Squibb, Eisai Co. Ltd., Eli Lilly and Company, F. Hoffmann-La Roche AG, Merck & Co., Inc., Novartis International AG, Pfizer Inc., Sanofi S.A., Others|
|Unit Denominations||USD Million/Billion|
Moreover, remarkable improvements in existing healthcare facilities and rigorous R&D activities in the area of oncology are also driving the global market. In addition, the increasing public awareness about various available alternatives for AML treatment, coupled with the extensive adoption of targeted & combination therapies, are also promoting the overall market expansion.
However, the high costs associated with stem cell transplants, the risk of side effects from chemotherapy drugs, and stringent regulations on drug approvals are the prominent factors that might restrain the growth of the Global Acute Myeloid Leukemia (AML) Market through 2027.
Impact of Covid-19 on the Global Acute Myeloid Leukemia (AML) Market
The impact of the Covid-19 pandemic has been catastrophic for most industries worldwide, with the healthcare sector witnessing immense pressure and declining demand for Acute Myeloid Leukemia (AML) therapeutic products in 2020 amidst the crisis.
During the pandemic, governments of different countries imposed lockdowns & stringent movement restrictions, and all healthcare priorities shifted to attending only to Covid-19 cases. The temporary halt on various research & development activities associated with AML drugs & therapies, coupled with an exponential focus on developing cures & vaccines for coronavirus, considerably hampered the growth of the Global Acute Myeloid Leukemia (AML) Market.
However, some studies stated that patients with blood cancer, especially those suffering from AML, lymphoma, & multiple myeloma, are at a higher risk of getting affected by Covid-19. As a result, AML treatment was performed regularly amidst the crisis, and therefore, there was a limited impact of the Covid-19 pandemic on AML therapeutic sales in 2020.
Based on Treatment:
Amongst them all, chemotherapy is the prime treatment given to most people with AML. Drugs used are the combination of Anthracyclines like cerubidine (daunorubicin) or idamycin (idarubicin) and Cytarabine.
Cytarabine holds the largest share in the Global Acute Myeloid Leukemia (AML) Market, and the same trend is expected during 2022-27. It attributes primarily to its effectiveness in AML treatment, which has resulted in high survival rates of patients, coupled with its ability & increased tolerance to be used in combination with other drugs.
Moreover, several pharmaceutical companies worldwide are receiving approvals by regulatory authorities for Cytarabine to treat newly-diagnosed t-AML or AML-MRC patients. As a result, the extensive use of Cytarabine in the chemo-treatment of patients suffering from AML is driving the Global Acute Myeloid Leukemia (AML) Market.
In addition, chemotherapy and targeted therapy are combined, followed by a stem cell transplant, in order to increase the overall efficacy of AML treatment. Targeted drugs like FLT3 inhibitors (Rydapt (Midostaurin), Xospata (Gilteritinib)), IDH inhibitors (Tibsovo (Ivosidenib), Idhifa (Enasidenib)), Mylotarg (gemtuzumab ozogamicin), BCL2 inhibitor (Venclexta (Venetoclax)), etc., work differently from standard chemotherapy drugs. They can sometimes be helpful even when chemo alone is not or can be used alongside chemo to yield enhanced efficacy.
Since the doses of chemotherapy drugs are determinate, as a higher number can cause serious side effects, doctors prefer SCT (Stem Cell Transplant), also known as a BMT (Bone Marrow Transplant), to give higher doses of chemotherapy. Once SCT is over, AML patients get an infusion of blood-forming stem cells in order to restore their bone marrow.
Based on End-Users:
Here, hospitals are expected to account for the largest market share throughout 2027 as they are the primary source of any treatment, including AML. The increasing patient pool of AML at hospitals across different countries worldwide, owing to the round-the-clock availability of various drugs & diagnosis equipment required for AML treatment, is driving the global market.
Moreover, governments of several countries worldwide are working on advancing their respective healthcare facilities with massive investments in hospitals to procure all medications & equipment associated with AML treatment to cater to varied patient requirements. In addition, hospital pharmacies observe a constant demand for refilling the prescribed medications after diagnosis or during the treatment. Hence, these aspects would continue driving the Global Acute Myeloid Leukemia (AML) Market across hospitals over the coming years.
Geographically, the Global Acute Myeloid Leukemia (AML) Market expands across:
Among all regions globally, North America holds the largest share in the Acute Myeloid Leukemia (AML) Market and shall continue its dominance even through 2027. The regional market would be driven primarily by the mounting prevalence of AML and the growing elderly population across North America.
Furthermore, excellent healthcare facilities, the burgeoning need for more advanced targeted therapies, massive funding in the development of pipeline drugs, and growing public awareness about AML treatments are further propelling the market growth.
In addition, various ongoing R&D activities, increasing drug approvals for AML treatment, and the extensive presence of leading pharmaceutical companies in the region further project lucrative prospects for the Acute Myeloid Leukemia (AML) Market in North America over the forecast years.
On the other hand, Asia-Pacific is set to experience notable market growth during 2022-27, mainly on account of rapid developments in the healthcare infrastructure, coupled with substantial government investments in bringing advanced cancer treatments.
Besides, the gradually increasing shift from traditional treatments toward targeted therapies across various hospitals in the region owing to their benefits like low collateral damage & remarkable efficacy is another crucial factor projected to boost the Asia-Pacific Acute Myeloid Leukemia (AML) Market in the years to come.
Key Questions Answered in the Market Research Report:
Frequently Asked Questions
A. The Global Acute Myeloid Leukemia (AML) Market is projected to witness around 13% CAGR during 2022-27.
A. The increasing instances of AML due to changing lifestyles, the mounting prevalence of genetic mutations, and the rapidly rising elderly population are the prime factors projected to drive the Global Acute Myeloid Leukemia (AML) Market through 2027. On the other hand, strict norms for drug approvals and high costs associated with stem cell transplantation are likely to restrict the growth of the global market in the years to come.
A. Targeted therapies are projected to provide lucrative prospects for the leading companies operating in the Global Acute Myeloid Leukemia (AML) Market over the forecast years.